Efficacy And Adverse Reactions Analysis Of Paclitaxel Liposome And Traditional Treatment Of Ovariancancer

ObjectiveTo compare the effectiveness and adverse reactions of paclitaxel liposome-combinedcarboplatin and traditional paclitaxel combined carboplatin for ovarian cancer, to evaluatethe advantages and disadvantages of the two chemotherapy regimens, and to provides abetter chemotherapy regimen for ovarian cancer.Methods65cases of ovarian cancer patients were collected in Linyi People’s Hospital fromJune2012to December2013. All patients received the ovarian cytoreductive surgery andpostoperative pathologic examination confirmed primary epithelial ovarian cancer. Allpatients were divided into two groups, the experimental group and the control group. Theexperimental group (30cases), was given the chemotherapy regimen of paclitaxelliposome combined carboplatin (135-175mg/m2) and the control group (35cases)traditional paclitaxel combined carboplatin (135-175mg/m2)All patients were treated6courses of chemotherapy with each three weeks as one period cycles.ResultsCompared with the paclitaxel combined carboplatin group, the paclitaxel liposomescombined carboplatin group didn’t show significant differences in the total effective rate(P=0.324), while it was significant superior in reducing some adverse reactions, such asmuscle and joint pain (P=0.013), peripheral neurotoxicity (P=0.023), nausea or vomiting(P=0.007), facial blushing (P=0.029) and rashes (P=0.021) trichomadesis (P=0.020). Butthere were no obvious differences between the two groups in dyspnea, diarrhea, bellyacheand blood system abnormalities.ConclusionsAs current clinical evidences shows, the paclitaxel liposomes combined carboplatin isas effective as the paclitaxel combined carboplatin in treating ovarian cancer, and it can reduce some of the adverse reactions. Therefore, the paclitaxel liposomes combinedcarboplatin is available as a new, safe and effective treatment for ovarian cancer. Due tothe small scale of our study, this conclusion has to be further proved with large-scale, anddouble-blind RCTs.